CD47 and acute lymphoblastic leukemia: Perhaps combination therapies of low-intensity chemotherapy with inotuzumab and blinatumomab given upfront, followed by CAR T-cell therapy, and the use of other investigational drugs such as anti-CD47 antibodies, could be offered more selectively to patients with R-R ALL and such high-risk features.